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Left Ventricular Hypertrophy and
Biomarkers of Cardiac Damage and Stress
in Aortic Stenosis
Elliot J. Stein , MD, MSTR; William F. Fearon , MD; Sammy Elmariah , MD, MPH; Juyong B. Kim , MD;
Samir Kapadia , MD; Dharam J. Kumbhani , MD; Linda Gillam , MD, MPH; Brian Whisenant , MD;
Nishath Quader, MD; Alan Zajarias, MD; Frederick G. Welt , MD; Anthony A. Bavry , MD, MPH;
Megan Coylewright , MD, MPH; Robert N. Piana, MD; Ravinder R. Mallugari, MBBS; Daniel E. Clark , MD;
Jay N. Patel, MD; Holly Gonzales, MD; Deepak K. Gupta , MD, MSCI; Anna Vatterott, MPH; Natalie Jackson, MPH;
Shi Huang, PhD; Brian R. Lindman , MD, MSCI
BACKGROUND: Left ventricular hypertrophy (LVH) is associated with increased mortality risk and rehospitalization after transcatheter aortic valve replacement among those with severe aortic stenosis. Whether cardiac troponin (cTnT) and NT-proBNP
(N-terminal pro-B-type natriuretic peptide) risk stratify patients with aortic stenosis and without LVH is unknown.
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METHODS AND RESULTS: In a multicenter prospective registry of 923 patients with severe aortic stenosis undergoing transcatheter aortic valve replacement, we included 674 with core-laboratory-measured LV mass index, cTnT, and NT-proBNP. LVH was
defined by sex-specific guideline cut-offs and elevated biomarker levels were based on age and sex cut-offs. Adjusted Cox
proportional hazards models evaluated associations between LVH and biomarkers and all-cause death out to 5 years. Elevated
cTnT and NT-proBNP were present in 82% and 86% of patients with moderate/severe LVH, respectively, as compared with
66% and 69% of patients with no/mild LVH, respectively (P<0.001 for each). After adjustment, compared with no/mild LVH,
moderate/severe LVH was associated with an increased hazard of mortality (adjusted hazard ratio [aHR], 1.34; 95% CI 1.01–
1.77, P=0.043). cTnT and NT-proBNP each risk stratified patients with moderate/severe LVH (P<0.05). In a model with both
biomarkers and LVH included, elevated cTnT (aHR, 2.08; 95% CI 1.45–3.00, P<0.001) and elevated NT-proBNP (aHR, 1.46; 95%
CI 1.00–2.11, P=0.049) were each associated with increased mortality risk, whereas moderate/severe LVH was not (P=0.15).
CONCLUSIONS: Elevations in circulating cTnT and NT-proBNP are more common as LVH becomes more pronounced but are
also observed in those with no/minimal LVH. As measures of maladaptive remodeling and cardiac injury, cTnT and NT-proBNP
predict post-transcatheter aortic valve replacement mortality better than LV mass index. These findings may have important
implications for risk stratification and treatment of patients with aortic stenosis.
Key Words: biomarkers ■ left ventricular hypertrophy ■ mortality ■ NT-proBNP ■ transcatheter aortic valve implantation ■
transcatheter aortic valve replacement ■ troponin

L

eft ventricular hypertrophy (LVH) often develops
in response to pressure overload from aortic stenosis (AS). Because increased wall thickness reduces wall stress, LVH has long been considered an
anticipated and compensatory response, presumably

advantageous to maintain cardiac performance.1
However, several studies have challenged the paradigm that hypertrophic remodeling in patients with AS
is adaptive.2–4 Recently, an adverse association between greater left ventricular mass index (LVMi) and
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CLINICAL PERSPECTIVE
What Is New?

• In a study with core laboratory measurements of
left ventricular (LV) mass index and biomarkers
of cardiac damage (cardiac troponin) and stress
NT-
proBNP (N-
terminal pro-B-type natriuretic
peptide), elevations in biomarkers were more
common as LV mass index increased and among
those with concentric or eccentric hypertrophy,
but the biomarkers were also frequently elevated
in those with no or minimal LV hypertrophy (LVH).
• cTnT and NT-proBNP were useful in risk stratifying patients with moderate/severe LVH and cardiac troponin risk stratified those with no/mild
LVH, and in combined models with biomarkers
and LVH, the biomarkers were each independently associated with mortality, whereas LVH
was not.

What Are the Clinical Implications?

• As measures of maladaptive remodeling and
cardiac injury, cardiac troponin and NT-proBNP
predict post-transcatheter aortic valve replacement mortality better than LV mass index, which
may have important implications for risk stratification and optimal treatment timing for patients
with aortic stenosis.
Downloaded from http://ahajournals.org by on December 7, 2022

Nonstandard Abbreviations and Acronyms
AS
cTnT
KCCQ
LVH
LVMi
NT-proBNP
TAVR

aortic stenosis
cardiac troponin
Kansas City Cardiomyopathy
Questionnaire
left ventricular hypertrophy
left ventricular mass index
N-terminal pro-B-type natriuretic
peptide
transcatheter aortic valve
replacement

worse clinical outcomes was shown among patients
with severe AS treated with transcatheter aortic valve
replacement (TAVR) in a study with a large number of
patients, core laboratory read echocardiograms, and
the longest follow-up period for such studies to date.5
While there was a continuous, linear association between greater LVMi and higher risk, the risk was most
clear for those who reached the threshold for moderate or severe LVH. Nonetheless, the risk for these
patients was modest.

The adverse prognosis associated with greater
LVMi is likely related to the maladaptive remodeling
that often accompanies it, characterized by fibrosis, ischemia, capillary rarefaction, and other injurious processes that presage diastolic and systolic
dysfunction.6–8 However, there are also physiologic
aspects to LV hypertrophy that presumably are not
associated with adverse outcomes. Measurement
of LVMi alone, then, does not allow for a distinction between the maladaptive versus adaptive aspects of hypertrophic remodeling in patients with
AS. In contrast, the biomarkers cardiac troponin T
(cTnT) 9–11 and NT-p roBNP (N-terminal pro-B -t ype
natriuretic peptide)10,12,13 are sensitive and specific
circulating measures of cardiac damage and stress
that do not reflect adaptive or physiologic cardiac
remodeling.14
In a multicenter prospective cohort of patients
with symptomatic severe AS undergoing TAVR with
core laboratory measurement of LVMi, cTnT, and NT-
proBNP, we evaluated the relationship between LVH
groups (based on degree of increase in LVMi and
based on remodeling type) and frequency and severity
of biomarker elevations and their respective associations with mortality after TAVR. We hypothesized that
the association between LVH and biomarkers would
be significant but modest, indicating that they are related but not redundant indicators of myocardial health.
Further, we hypothesized that the biomarkers would be
more strongly associated with the risk of mortality after
TAVR than LVH and would risk stratify both those with
minimal and more marked LVH.

METHODS
The authors will make the data, statistical analyses,
and methods available to any researcher for the purposes of replicating the findings herein.

Study Population
The study population was drawn from a prospective
multicenter registry of patients with severe, symptomatic native valve AS who underwent TAVR with a balloon expandable or self-expanding transcatheter heart
valve between May 2014 and February 2017. The 11
enrolling centers were all in the United States (listed
in Data S1). Severe AS was defined as aortic valve
area index <0.6 cm2/m2, transvalvular mean gradient
≥40 mm Hg, or peak jet velocity ≥4 m/sec. For this
analysis, we included patients with (1) pre-TAVR echocardiographic images transferred to the coordinating
center allowing for centralized measurement of LVMi
and (2) measurements of plasma cTnT and NT-proBNP
obtained on a pre-
TAVR banked blood specimen.
Institutional review board approval was obtained at
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each enrolling site, and all enrollees provided written,
informed consent.

Biomarkers
Venous blood was collected into EDTA-
coated and
silicone-coated tubes, centrifuged for 15 minutes at
1500g within 30 minutes of phlebotomy. Plasma aliquots were stored at −80 °C at each local site and
at the coordinating center. Biomarkers were collected
a mean of 4±15 days before TAVR. Frozen samples
were shipped on dry ice to the coordinating center
where all assays were performed in a single batch on
previously unthawed aliquots. cTnT and NT-
proBNP
concentrations were measured with electrochemiluminescence immunoassays (Elecsys Troponin T Gen
5 STAT and Elecsys proBNP II, Roche Diagnostics,
Basel, Switzerland). Based on assay reference ranges,
normal cTnT was defined as <14 and <22 pg/mL for
female and male patients, respectively. Normal NT-
proBNP was also defined based on assay reference
range as <125 and <450 pg/mL for patients aged
<75 years and ≥75 years, respectively.

Echocardiography
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Transthoracic echocardiograms were obtained a mean
of 58±62 days prior to TAVR. Images were transferred to
the coordinating center for centralized review and measurement in a core laboratory. LVMi was calculated with
the linear method cube formula using 2D linear measurements from the parasternal long-axis view as recommended by the American Society of Echocardiography
(ASE) and was indexed to body surface area.15–17
Categories of LVH were defined based on sex-specific
cut-offs as recommended: no LVH (<116 g/m2 for male,
<96 for female patients); mild LVH (≥116 to <132 g/m2 for
male, ≥96 to <109 g/m2 for female patients); moderate
LVH (≥132 to ≤148 g/m2 for male, ≥109 to ≤121 g/m2 for
female patients); and severe LVH (>148 g/m2 for male,
>121 g/m2 for female patients).15 Relative wall thickness (RWT) was calculated as RWT=((posterior wall
thickness*2)/LV end-
diastolic dimension). LV remodeling geometry groups—normal geometry, concentric
remodeling, concentric hypertrophy, and eccentric
hypertrophy—
were also defined based on RWT and
sex-based LVMi cut-offs according to ASE criteria.15

Vital Status
Dates of death and dates of last known time alive were
obtained through a combination of site report, phone
calls, clinic follow-up data in the electronic medical
record, or online obituary searches. A final comprehensive assessment for vital status was performed between March and June 2020. Patients were censored
at the date last known to be alive.

LVH and Biomarkers in Aortic Stenosis

Statistical Analysis
For baseline clinical and echocardiographic data,
continuous variables were reported as medians with
interquartile range, and categorical variables were reported as percent and number of patients. Patients
were grouped dichotomously into no/mild and moderate/severe LVH classes based on prior studies associating moderate and severe LVH with increased
risk of death and rehospitalization.5 Patients were also
classified as either having “normal” or “elevated” cTnT
and NT-proBNP, as described above. Intergroup comparisons were made using Pearson Chi-
squared or
Kruskal-Wallis test as appropriate. Pairwise tests between groups were performed using the Pearson Chi-
squared or Wilcoxon test as indicated.
Survival analysis was conducted to examine the
relationships between LVH groups, cTnT, NT-proBNP,
and mortality after TAVR. Survival time was calculated
from date of TAVR procedure to date of censoring.
Kaplan-
Meier plots were presented, and intergroup
comparisons were made using the log-rank test. In addition, a series of Cox proportional hazard regression
models were conducted. Hazard ratio (HR) and 95% CI
were calculated to present the associations between
risk of all-cause mortality between LVH, cTnT, and NT-
proBNP. Adjusted HRs (aHRs) are reported. Covariates
in adjusted models were selected a priori based on
clinical plausibility and prior studies and included: age,
sex, BMI, transvalvular mean gradient, aortic valve
area, low flow (stroke volume index <35 mL/m2), STS-
PROM score, hemoglobin, creatinine clearance, TAVR
approach (transfemoral versus non-transfemoral), left
ventricular ejection fraction (LVEF), oxygen-dependent
lung disease, coronary artery disease, diabetes mellitus, New York Heart Association functional class,
mitral regurgitation severity, atrial fibrillation or atrial
flutter, and presence of active cancer. Nonlinear terms
for continuous covariates were included as restricted
cubic spline with 3 knots. There were no missing data
for survival, LVMi, cTnT, NT-proBNP, and missingness
of adjustment variables was minimal (<1%). In addition,
cTnT and NT-proBNP concentrations were log transformed and examined as continuous predictors in
Cox models by including restricted cubic spline with 3
knots. Spline plots were also generated with LVMi as a
continuous variable, and the data were segregated into
those with and without biomarker elevations. Potential
interactions between the biomarkers and between the
biomarkers and LVH groups were assessed.
Ordinal regressions were conducted to examine
the relationships between LVH, cTnT, NT-proBNP and
Kansas City Cardiomyopathy Questionnaire (KCCQ)
score 30-
days post-
procedure, and 1-
year post-
procedure. Baseline KCCQ scores were adjusted for
in ordinal regressions. Model-estimated KCCQ score
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differences between LVH, cTnT, and NT-
proBNP
groups at 30-days and 1-year post-procedure were
presented.
All statistical computations were performed using R
3.3.1 (R Foundation for Statistical Computing, Vienna,
Austria) and associated packages. Statistical significance was defined as a P-value <0.05, where all P-
values were two tailed. Graphics were generated in R
or Prism 9 (Graphpad Software, San Diego, CA).

RESULTS
Patient Population and Baseline
Characteristics

Downloaded from http://ahajournals.org by on December 7, 2022

Our multicenter, prospective registry of patients with
severe AS who received TAVR included 923 patients.
Of these, our analytic cohort included 674 with LVMi
measured in the core laboratory and biomarkers
measured (Figure S1). Baseline characteristics of included versus excluded patients are shown in Table
S1. Baseline characteristics and echocardiographic
data are displayed for our analytic cohort in Tables 1
and 2, respectively. The final study population consisted of 44% female patients with median age of
83.5 years and median STS of 4.2. Transfemoral access was used in 88% of procedures and rates of
stroke or death prior to discharge were <2%. Median
duration of follow-up was 3 years and 279 patients
died. Follow-up at 1 year was completed for 564 patients; at 2 years for 439 patients; 3 years for 338 patients; and 4 years for 125 patients. The median (IQR)
biomarker concentrations were 25 pg/mL (16–41 pg/
mL) for cTnT and 1380 pg/mL (622–3372 pg/mL) for
NT-
proBNP. Approximately 50% had at least mild
hypertrophy and the vast majority had either concentric remodeling (41%) or concentric hypertrophy
(41%). Among those with no/mild LVH and moderate/
severe LVH, biomarker elevations were associated
with higher STS score and reduced kidney function,
among other differences (Tables S2 and S3).

LVH and Biomarker Elevations
Based on sex-specific definitions of LVH, 341 (51%) patients had no LVH (41% of the female, 58% of the male
patients), 123 (18%) patients had mild LVH (19% of the
female, 18% of the male patients), 88 (13%) patients had
moderate LVH (16% of the female, 11% of the male patients), and 122 (18%) patients had severe LVH (24% of
the female, 13% of the male patients). When stratified according to LV geometry, 62 (9%) had normal geometry
(2% of female, 7% of male patients), 279 (42%) had concentric remodeling (16% of female, 26% of male patients),
278 (41%) had concentric hypertrophy (22% of the female,
19% of the male patients), and 55 (8%) had eccentric hypertrophy (4% of the female, 5% of the male patients).

LVH and Biomarkers in Aortic Stenosis

Table 1. Baseline Characteristics
Characteristic

All patients

Patients, No.

674

Age, y

83.5 (77.3–87.8)

Sex, % female (n)

43.8% (295)

Body mass index, kg/m2

27.4 (24.0– 31.5)

Race, % White (n)

96.4% (650)

STS score

4.2 (3.0– 6.4)

Hypertension

92.9% (626)

SBP, mm Hg

130 (118–146)

DBP, mm Hg

68 (61–76)

Diabetes

36.8% (248)

Coronary artery disease

71.1% (481)

Myocardial infarction

22.5% (150)

Coronary revascularization

47.6% (321)

Atrial fibrillation/flutter

41.6% (280)

Creatinine clearance, mL/min

50.8 (36.8– 68.2)

Dialysis

3.3% (22)

Heart failure class
NYHA I

3.6% (23)

NYHA II

25.6% (164)

NYHA III

58.8% (377)

NYHA IV

12.0% (77)

Oxygen-dependent lung disease

9.1% (61)

Active cancer

5.3% (36)

Prior stroke

11.9% (80)

Hemoglobin, g/dL

12.2 (11.0–13.4)

TAVR access, % transfemoral (n)

87.7% (591)

Post-procedural stroke

1.5% (9)

Post-procedural death

1.3% (9)

Plasma cTnT, pg/mL

25.2 (16.2– 41.4)

Elevated cTnT

70.9% (478)

Plasma NT-proBNP, pg/mL

1380 (622–3372)

Elevated NT-proBNP

74.2% (500)

Elevated both cTnT and
NT-proBNP

57.7% (389)

Data for each characteristic is displayed as either a percentage (number
of patients) or as median (IQRQ1–IQRQ3), where “IQR” is interquartile range.
cTnT indicates cardiac troponin; DBP, diastolic blood pressure; NYHA,
New York Heart Association; SBP, systolic blood pressure; STS, Society of
Thoracic Surgeons; and TAVR, transcatheter aortic valve replacement.

The frequency of biomarker elevations in all patients and stratified by sex are shown for LVH groups
based on LVMi (Figure 1) and LV remodeling geometry (Figure 2). Absolute concentrations of biomarkers
and the distribution of those with 0, 1, and 2 biomarker
elevations are shown for these same LVH groups in
Figures S2 and S3, respectively. Pair-wise comparisons are reported in Tables S4 and S5. Overall, the
frequency of biomarker elevations (individually and
combined) and the absolute levels of the biomarkers
increase as LVH becomes more severe. With respect
to LV remodeling geometry, biomarker elevations are
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Table 2. Baseline Echocardiographic Characteristics
Characteristic

All patients

LV mass, g

205.1 (164.0–246.0)

LV mass index, g/m2

107.4 (90.8–125.9)

LV remodeling type
Normal geometry

9.2% (62)

Concentric remodeling

41.4% (279)

Concentric hypertrophy

41.2% (278)

Eccentric hypertrophy

8.2% (55)

Left ventricular hypertrophy grade
No

50.6% (341)

Mild

18.2% (123)

Moderate

13.1% (88)

Severe

18.1% (122)

LV ejection fraction, %

61.4 (52.8–66.1)

LV stroke volume index, mL/m2

36.4 (29.3–44.2)

LV end-diastolic diameter, mm

44.2 (40.1– 49.5)

LV end-systolic diameter, mm

29.3 (25.2–35.2)

LV relative wall thickness,
dimensionless

0.54 (0.45–0.64)

LV septum thickness, mm

12.6 (11.3–14.3)

LV posterior wall dimension, mm

11.9 (10.6–13.4)
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LV outflow tract diameter, mm

2.0 (1.9–2.1)

AV area, mm2

0.72 (0.59–0.86)

AV area index, mm2

0.38 (0.31–0.46)

AV mean gradient, mm Hg

38.3 (31.5– 49.2)

Aortic valve peak velocity, m/s

4.1 (3.7–4.5)

Low flow

44.6% (296)

Moderate or severe AR

4.2% (27)

Moderate or severe MR

3.7% (25)

Data for each characteristic is displayed as either a percentage (number
of patients) or as median (IQRQ1–IQRQ3), where “IQR” is interquartile range.
AR indicates aortic regurgitation; AV, aortic valve; LV, left ventricular; and MR,
mitral regurgitation.

most common in those with concentric hypertrophy
or eccentric hypertrophy. These patterns are generally similar in male and female patients. There was a
significant, but modest, correlation between log(cTnT)
and log(NT-proBNP) levels (r=0.49, P<0.001) among all
patients.

LVH, Biomarkers, and All-Cause Death
Compared with no/mild LVH with a KM-estimated 5-
year mortality of 58.1%, moderate/severe LVH with a
KM-estimated 5-year mortality of 69.6% was associated with increased mortality risk, although this was
of borderline significance (Figure 3A). After adjustment,
compared with no/mild LVH, moderate/severe LVH
was independently associated with a higher hazard
of mortality (aHR, 1.34; 95% CI 1.01–1.77, P=0.043)
(Table 3). While the 4-level categorical variable for cardiac remodeling geometry was associated with an

increased risk of mortality (Figure 3B, Table 3), none of
the remodeling groups was associated with a significantly increased risk of mortality when compared with
normal geometry (Table 3). The associations between
elevated cTnT (Figure 3C) and elevated NT-
proBNP
(Figure 3D) and increased mortality risk were significant in unadjusted and adjusted analyses (Table 3).
We then combined LVH groups and biomarkers
in additional analyses. Among those with moderate/
severe LVH, compared with those with a normal biomarker level, an increased cTnT or NT-proBNP was
associated with increased mortality risk (Table 3 and
Figure 4A and 4B). Among those with no/mild LVH,
compared with those with a normal biomarker level,
an increased cTnT but not an elevated NT-proBNP was
associated with increased mortality risk (Table 3 and
Figure 4A and 4B). When each biomarker was included
in models with LVH, each biomarker was independently
associated with increased mortality risk, whereas LVH
was not (Table 3). Similarly, in the model with both biomarkers and LVH included, an increased cTnT (aHR
2.08; 95% CI 1.45–3.00, P<0.001) and increased NT-
proBNP (aHR, 1.46; 95% CI 1.00–2.11, P=0.049) were
each associated with increased mortality risk, whereas
moderate/severe LVH was not (P=0.15). There were no
significant interactions between each biomarker and
LVH category (based on severity or cardiac remodeling
geometry) or between cTnT and NT-proBNP.
The associations between continuous LVMi and log-
transformed biomarker levels and 5-year survival probability were also evaluated (Figure 5). Irrespective of LVH
group, a higher log-transformed cTnT was associated
with lower 5-year survival probability until leveling off at
a log-transformed cTnT value of ~4.1 (corresponding to
an absolute level of 60 pg/mL). For those with moderate/
severe LVH, the 5-year survival probability was ~90% for
an absolute cTnT value of 4.5 pg/mL and ~50% for an
absolute cTnT value of 22 pg/mL (Figure 5A). Irrespective
of LVH group, a higher log-transformed NT-proBNP was
linearly associated with a lower probability of 5-year survival. For those with moderate/severe LVH, 5-year survival probability was ~77% for an absolute NT-proBNP
value of 17 versus ~50% for an absolute NT-proBNP
value of 1100 pg/mL (Figure 5B). For both cTnT and NT-
proBNP, there was no significant interaction between
LVH group and biomarker level. When LVMi was treated
as a continuous variable, it was not associated with
worsened 5-year survival probability in either those with
elevated or normal cTnT or NT-proBNP (Figure 5C and
5D). Likewise, there was no significant interaction between biomarker elevation group and LVMi.

Quality of Life
After adjusting for baseline KCCQ, there were no significant associations between moderate/severe LVH or
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Figure 1. Sex-stratified distribution of biomarker elevations vs left ventricular hypertrophy (LVH) severity.
The percentage of patients with elevations of cardiac troponin (cTnT), NT-proBNP (N-terminal pro-B-t ype natriuretic peptide), or both
are displayed for each LVH category for female patients, male patients, and female+male patients. P values correspond to the results
of the chi square test for trend in proportions. Mod indicates moderate; and Sev, severe.

elevated biomarkers and KCCQ at 30-day or 1-year
post-TAVR (Table S6).

DISCUSSION
In this multicenter prospective registry study of patients with severe, symptomatic AS who underwent
TAVR with core-laboratory measurement of LVMi, cTnT,
and NT-proBNP, we made several observations. First,

the frequency of biomarker elevations (individually and
combined) and the absolute levels of the biomarkers
increase as LVH becomes more severe; related to this,
biomarker levels are highest in those with concentric
hypertrophy or eccentric hypertrophy geometries.
Nonetheless, there were many patients with no/mild
LVH or normal geometry or concentric remodeling
with elevated biomarkers and many with more significant hypertrophy without elevation in biomarkers.
Second, our study recapitulates earlier PARTNER trial
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Figure 2. Sex-stratified distribution of biomarker elevations vs left ventricular (LV) remodeling geometry.
The percentage of patients with elevations cardiac troponin (cTnT), NT-proBNP (N-terminal pro-B-t ype natriuretic peptide), or both are
displayed for each LV geometry category for female patients, male patients, and female+male patients. P values correspond to the
results of the chi square test for trend in proportions. CH indicates concentric hypertrophy; CR, concentric remodeling; EH, eccentric
hypertrophy; and NG, normal geometry.

data which demonstrated that more marked LVH was
associated with an increased hazard of mortality after
TAVR.5 Third, cTnT and NT-proBNP were useful in risk
stratifying patients with moderate/severe LVH and cTnT
risk stratified those with no/mild LVH. Fourth, in combined models with biomarkers and LVH, the biomarkers were each independently associated with mortality,
whereas LVH was not. Collectively, these data indicate

that as more sensitive and specific markers of myocardial damage and stress, cTnT and NT-proBNP predict post-TAVR mortality better than LVMi. They detect
patients with no or minimal LVH at increased risk due
to myocardial damage and stress from other causes
and they identify patients with moderate or severe
LVH at lower risk because their hypertrophy is likely
more adaptive. These findings may have important
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Figure 3. Kaplan-Meier estimates of survival probability for (A) no/mild left ventricular hypertrophy (LVH) vs moderate/
severe LVH, (B) normal, concentric remodeling, concentric hypertrophy, and eccentric hypertrophy geometries, (C) elevated
cardiac troponin (cTnT) vs normal cTnT, and (D) elevated NT-proBNP (N-terminal pro-B -t ype natriuretic peptide) vs normal
NT-proBNP.

implications for risk stratification and treatment of patients with AS.
Prior studies have separately demonstrated the adverse prognosis associated with significant LVH and
biomarkers of cardiac damage and stress (including
cTnT and NT-proBNP) in patients with severe AS undergoing aortic valve replacement.5,18–20 To our knowledge, though, this is the first study that examined the

prognostic significance of LVH and biomarkers together
in integrated analyses with LVMi and biomarkers measured in core laboratories. Our finding of an adjusted
association between more marked LVH and increased
mortality risk after TAVR is consistent with the observation from the PARTNER trial linking increased LVMi to
increased 5-year all-cause mortality.5 Nonethless, our
results also show that the prognostic significance of
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Table 3. Adjusted Cox Proportional Hazard Models for All-Cause Mortality Over 5 Years
Adjusted HR (95% CI)

P value

1.34 (1.01–1.77)

0.043

1 Normal geometry (referent)

…

…

2 Concentric remodeling

1.35 (0.78–2.34)

0.28

3 Concentric hypertrophy

1.68 (0.98–2.86)

0.059

4 Eccentric hypertrophy

0.85 (0.41–1.75)

0.65

2.21 (1.54–3.17)

<0.001

1.64 (1.13–2.37)

0.009

1 Moderate/severe LVH vs no/mild LVH*

1.27 (0.96–1.69)

0.092

2 Elevated cTnT vs normal cTnT*

2.17 (1.51–3.12)

<0.001

…

…

2

Moderate/severe LVH compared with no/mild LVH (X =4.1, P=0.043)
Moderate/severe LVH vs no/mild LVH
2

Patterns of cardiac remodeling (X =8.55, P=0.036)

Biomarkers evaluated separately
cTnT evaluated alone (X 2=18.44, P<0.001)
1 Elevated cTnT vs normal cTnT
2

NT-proBNP evaluated alone (X =6.86, P=0.009)
1 Elevated NT-proBNP vs normal NT-proBNP
Biomarkers evaluated (individually) with LVH
cTnT evaluated with LVH (X 2=17.81, P<0.001)

Groups according to LVH and cTnT elevation (X 2=22.83 P<0.001)
1 No/mild LVH (normal cTnT) (referent)
2 No/mild LVH (elevated cTnT)

1.92 (1.28–2.88)

0.0016

3 Moderate/severe LVH (normal cTnT)

0.80 (0.35–1.84)

0.60

4 Moderate/severe LVH (elevated cTnT)

2.61 (1.68–4.06)

<0.001

1 Moderate/severe LVH vs no/mild LVH*

1.29 (0.97–1.71)

0.075

2 Elevated NT-proBNP vs normal NT-proBNP*

1.59 (1.10–2.31)

0.014

Group 4 vs 3 (P=0.004); group 4 vs 2 (P=0.04)
NT-proBNP evaluated with LVH (X 2=6.67, P<0.036)
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Groups according to LVH and NT-proBNP elevation (X 2=11.27, P=0.01)
1 No/mild LVH (normal NT-proBNP) (referent)

…

…

2 No/mild LVH (elevated NT-proBNP)

1.43 (0.95–2.17)

0.090

3 Moderate/severe LVH (normal NT-proBNP)

0.86 (0.37–2.01)

0.72

4 Moderate/severe LVH (elevated NT-proBNP)

1.96 (1.26–3.06)

0.0031

1 Elevated cTnT vs normal cTnT

2.08 (1.45–3.00)

<0.001

2 Elevated NT-proBNP vs normal NT-proBNP

1.46 (1.00–2.11)

0.049

3 Moderate/severe LVH vs no/mild LVH

1.23 (0.93–1.64)

0.15

Group 4 vs 3 (P=0.046); group 4 vs 2 (P=0.04)
Biomarkers evaluated (combined) and LVH

Hazard ratios adjusted for age, sex, Society of Thoracic Surgeons score, body mass index, transvalvular mean gradient, aortic valve area, low flow,
transcatheter aortic valve replacement approach, creatinine clearance, diabetes mellitus, coronary artery disease, New York Heart Association functional
class, hemoglobin, presence of atrial fibrillation or flutter, oxygen dependence, presence of active cancer, left ventricular ejection fraction and presence of mitral
regurgitation.
cTnT indicates cardiac troponin; HR, hazard ratio; LVH, left ventricular hypertrophy; and NT-proBNP, N-terminal pro-B-type natriuretic peptide.
*HRs and P values are based on the models after removing nonsignificant interaction terms.

the biomarkers eclipse that of LVMi alone. Taken as a
whole, the risk associated with greater LVH observed
in prior studies may be associated with the frequent
and severe cardiac damage and stress (indicated by
more common and greater elevations in cTnT and
NT-proBNP) rather than increased LV mass per se. In
non-AS populations, consistent with our findings, others have shown that cTnT and NT-proBNP are useful in
risk stratifying individuals with LVH.14

We and others have found that greater hypertrophy is associated with more frequent and greater elevations in biomarkers of cardiac damage and stress,
but here we also observed frequent elevations in
these markers among those without significant LVH.9
Accordingly, a complex biology is at work contributing
to cardiac damage and stress in the pressure overloaded heart; the mechanisms include hypertrophy but
also extend beyond it to include other processes. Prior
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Figure 4. Kaplan-
Meier estimates of survival probability in those with moderate/severe vs no/mild left ventricular
hypertrophy (LVH) in (A) elevated vs normal cardiac troponin (cTnT) and (B) elevated vs normal NT-proBNP (N-terminal pro-
B-t ype natriuretic peptide).
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studies have demonstrated that these mechanisms
include fibrosis (diffuse and replacement), inflammation, autophagy and myocyte degeneration, and capillary rarefaction and impaired myocardial flow reserve
contributing to ischemia, among others.8,21–26 Overall,
these processes may tend to track with the amount of
hypertrophy, but they are not completely overlapping
and inter-changeable pathobiologies. The biomarkers
of cardiac damage and stress are a more sensitive and
specific barometer for all these maladaptive responses
to pressure overload, whereas LVMi alone is relatively
imprecise.9,10,23 While some of the processes and pathways that contribute to cardiac damage and stress in
the pressure overloaded heart are known, more work
is needed to elucidate these and other mechanisms
to identify therapeutic targets. Collectively, our findings
point to the need to explore the molecular underpinnings of the response to pressure overload from AS
to better understand patient risk and potential targets for intervention. These studies ought to include
and integrate gross/macroscopic cardiac phenotypes
(e.g., LVH, systolic/diastolic function), tissue-level phenotypes (e.g., diffuse and replacement fibrosis), and
molecular pathway analysis underlying these cardiac
phenotypes.
For personalized risk stratification for post-AVR
outcomes, the presence and severity of LVH alone
is insufficient as LVH is a heterogeneous process.
Better than an isolated measure of LVMi, biomarkers of cardiac damage and stress precisely, cheaply,
and reliably identify a maladaptive response to pressure overload and risk stratify patients with severe

AS with and without LVH. To mitigate risk from cardiac damage and stress, earlier AVR to unload the
heart before cardiac injury develops or becomes
more pronounced may improve post-
AVR outcomes. Relevant to this, biomarker-based strategies
employing cTnT and NT-proBNP have already been
proposed to guide treatment decisions for diabetes
and hypertension.27,28 Furthermore, adjunctive medical therapy targeting pathobiological processes
that result in cardiac damage and stress—including
hypertrophic remodeling but also fibrosis, inflammation, etc.—may protect the heart in the face of
pressure overload during progressive AS and yield
better post-AVR outcomes.
There are several limitations to consider when interpreting these findings. We may have been under-
powered to detect a synergistic relationship between
LVH and biomarkers with respect to post-TAVR risk.
Our cohort lacks follow-up echocardiographic data to
evaluate regression of LVH based on biomarker levels.
Data on rehospitalization post-TAVR was not collected.
Patients were not systematically assessed for cardiac
amyloid and the cohort was not very racially diverse.
Finally, all patients had symptomatic severe AS, so any
extrapolation to patients without symptoms and potential implications for optimal timing of AVR require additional study.

CONCLUSIONS
Among patients with severe symptomatic AS undergoing TAVR, elevations in biomarkers of cardiac

J Am Heart Assoc. 2022;11:e023466. DOI: 10.1161/JAHA.121.02346610

Stein et al

LVH and Biomarkers in Aortic Stenosis

Downloaded from http://ahajournals.org by on December 7, 2022

Figure 5. Relationship between 5-year survival and biomarker concentration.
Shown are the 5-year survival probability with respect to (A) log-transformed cTnT stratified by moderate/severe left ventricular
hypertrophy (LVH) and no/mild LVH, where Pinteraction is defined as p([cTnT] * LVMi) and (B) log-transformed NT-proBNP (N-terminal
pro-B-type natriuretic peptide) stratified by moderate/severe LVH and no/mild LVH, where Pinteraction is defined as p([NT-proBNP] *
LVMi). LVMi is a dichotomous variable in both (A and B). 5-year survival probability with respect to continuous LVMI as subdivided
by (C) normal cTnT and elevated cTnT level and (D) normal NT-proBNP and elevated NT-proBNP level. Pinteraction is defined as p(LVMI *
[cTnT]) and p(LVMI * [NT-proBNP]) for (C and D), respectively. cTnT indicates cardiac troponin; and LVMi, left ventricular mass index.

damage (cTnT) and stress (NT-proBNP) were more
common as LVMi increased and among those with
concentric or eccentric hypertrophy, but the biomarkers were also frequently elevated in those with
no or minimal LVH. cTnT and NT-proBNP were useful
in risk stratifying individuals with and without LVH. In
combined models, each of the biomarkers was independently associated with mortality after TAVR,
whereas LVH was not. Collectively, these data indicate that as more sensitive and specific markers of
myocardial damage and stress, cTnT and NT-proBNP
predict post-TAVR mortality better than LVMi. These
results should stimulate additional research on mechanisms underlying cardiac damage and stress in the
pressure overloaded heart to identify novel therapeutic targets and they inform the risk stratification of patients with severe AS with potential implications for
optimizing timing of AVR in asymptomatic patients.
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Data S1. List of Enrolling Centers
Barnes-Jewish Hospital, St. Louis, MO
Cleveland Clinic Foundation, Cleveland, OH
Dartmouth-Hitchcock Medical Center, Lebanon, NH
Intermountain Heart Institute, Murray, UT
Massachusetts General Hospital, Boston, MA
Morristown Medical Center, Morristown, NJ
Stanford Medical Center, Palo Alto, CA
University of Texas Southwestern Medical Center, Dallas, TX
University of Utah Hospital, Salt Lake City, UT
Vanderbilt University Medical Center, Nashville, TN
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Table S1. Baseline characteristics in included versus excluded patients
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Characteristic
Patients [N]
Age [y]
Sex [% female (n)]
Body mass index [kg / m2]
Race [% non-white (n)]
STS score
Hypertension
SBP [mmHg]
DBP [mmHg]
Diabetes
Coronary Artery Disease
Myocardial infarction
Coronary Revascularization
Atrial fibrillation / flutter
Creatinine clearance [mL / min]
Dialysis
Heart failure class
NYHA I
NYHA II
NYHA III
NYHA IV
Oxygen-dependent lung disease
Active cancer
Prior stroke
Hemoglobin [g / dL]
TAVR access [% transfemoral (n)]
Post-procedural stroke
Post-procedural death
Plasma ntProBNP [pg / mL]*
Plasma cTnT [pg / mL]*
LV mass index [g / m2]*
LV mass [g]
LV ejection fraction [%]
LV stroke volume index [mL / m2]
LV end-diastolic diameter [mm]
LV end-systolic diameter [mm]
LV relative wall thickness [dimensionless]
LV septum thickness [mm]
LV posterior wall dimension [mm]
LV outflow tract diameter [mm]
AV area [mm2]
AV area index [mm2]
AV mean gradient [mmHg]
Aortic valve peak velocity [m / s]

Excluded from Study
249
81.7 (74.7 – 86.6)
41.4% (103)
27.7 (24.5 – 32.6)
3.6% (5)
4.1 (2.5 – 6.6)
92.3% (229)
131 (118 – 145)
69 (60 – 77)
43.8% (109)
61.0% (152)
23.2% (57)
27.6% (68)
36.7% (91)
55.3 (38.7 – 74.4)
4.0% (10)

Included in Study
674
83.5 (77.3 – 87.8)
43.8% (295)
27.4 (24.0 – 31.5)
3.5% (24)
4.2 (3.0 – 6.4)
92.9% (626)
130 (118 – 146)
68 (61 – 76)
36.8% (248)
71.4% (481)
22.5% (150)
32.6% (219)
41.6% (280)
50.8 (36.8 – 68.2)
3.3% (22)

All Patients
923
83.0 (76.6 – 87.6)
43.1% (398)
27.5 (24.2 – 31.7)
3.6% (33)
4.2 (2.8 – 6.4)
92.7% (855)
131 (118 – 146)
68 (60 – 76)
38.7% (357)
68.6% (633)
22.7% (207)
31.3% (287)
40.3% (371)
52.1 (37.3 – 70.0)
3.5% (32)

2.1% (5)
20.5% (48)
65.8% (154)
11.5% (27)
13.7% (34)
5.6% (14)
10.4% (26)
12.3 (11.0 – 13.7)
90.8% (226)
3.9% (9)
0% (0)
1064 (521 – 2512)
23.0 (13.7 – 40.7)
117.1 (94.3 – 130.9)
213.6 (177.8 – 250.3)
60.0 (50.0 – 66.6)
35.6 (28.5 – 43.9)
23.5 (20.8 – 25.9)
29.6 (24.0 – 36.1)
0.57 (0.47 – 0.69)
13.5 (11.9 – 15.8)
12.4 (10.9 – 14.0)
1.98 (1.88 – 2.12)
0.70 (0.60 – 0.85)
0.37 (0.30 – 0.44)
40.0 (31.6 – 50.1)
4.1 (3.7 – 4.6)

3.6% (23)
25.6% (164)
58.8% (377)
12.0% (77)
9.1% (61)
5.3% (36)
11.9% (80)
12.2 (11.0 – 13.4)
87.7% (591)
1.5% (9)
3.1% (3)
1380 (622 – 3372)
25.2 (16.2 – 41.4)
107.4 (90.8 – 125.9)
205.1 (164.0 – 246.0)
61.4 (52.8 – 66.1)
36.4 (29.3 – 44.2)
23.4 (20.8 – 26.2)
29.3 (25.2 – 35.2)
0.54 (0.45 – 0.64)
12.6 (11.3 – 14.3)
11.9 (10.6 – 13.4)
1.99 (1.87 – 2.11)
0.72 (0.59 – 0.86)
0.38 (0.31 – 0.46)
38.3 (31.5 – 49.2)
4.1 (3.7 – 4.5)

3.2% (28)
24.2% (212)
60.7% (531)
11.9% (104)
10.3% (95)
5.4% (50)
11.5% (106)
12.3 (11.0 – 13.5)
88.5% (817)
2.2% (18)
2.6% (3)
1292 (602 – 3274)
25.1 (15.8 – 41.3)
107.9 (91.3 – 127.2)
206.1 (165.8 –246.2)
61.2 (52.1 – 66.2)
36.4 (29.1 – 44.1)
23.4 (20.8 – 26.2)
29.3 (25.0 – 35.4)
0.54 (0.45 – 0.64)
12.7 (11.4 – 14.4)
11.9 (10.6 – 13.5)
1.99 (1.87 – 2.12)
0.72 (0.59 – 0.86)
0.38 (0.31 – 0.45)
38.6 (31.5 – 49.3)
4.1 (3.7 – 4.6)

p-value
0.0061
0.5132
0.6771
0.472
0.0851
0.782
0.761
0.771
0.552
0.0032
0.8362
0.1522
0.1782
0.031
0.5792
0.2252

0.0412
0.8672
0.122
0.2221
0.1932
0.0362
0.4652
0.0691
0.3661
0.0641
0.231
0.441
0.4691
0.861
0.8231
0.0671
<0.0011
0.1011
0.6051
0.8911
0.4111
0.3581
0.6611

Low flow
Moderate or severe AR
Moderate or severe MR

48.7% (56)
12.2% (27)
13.5% (30)

44.6% (296)
9.2% (62)
14.0% (94)

45.2% (352)
9.9% (90)
13.8% (124)

0.4212
<0.0012
<0.0012

Data for each characteristic is displayed as either a percentage (number of patients) or as median (IQR Q1 – IQR Q3 ). Statistical tests
used were 1Wilcoxon test or 2Pearson test. LV = left ventricular, AV = aortic valve, AR = aortic regurgitation, MR = mitral
regurgitation. *To be included in the analytic cohort, subjects needed to have NTproBNP, cTnT, and LV mass index measured at
baseline. Some subjects excluded had one or more of those variables measured: NTproBNP (N=148), cTnT (N=148), and LV mass
index (N=86).
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Table S2. Baseline characteristics in the no/mild LVH group with respect to normal versus elevated biomarkers
Characteristic
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Patients [N]
Age [y]
Sex [% female (n)]
Body mass index [kg / m2]
Race [% non-white (n)]
STS score
Hypertension
SBP [mmHg]
DBP [mmHg]
Diabetes
Coronary artery disease
Myocardial infarction
Coronary Revascularization
Atrial fibrillation / flutter
Creatinine clearance [mL / min]
Dialysis
Heart failure class
NYHA I
NYHA II
NYHA III
NYHA IV
Oxygen-dependent lung disease
Active cancer
Prior stroke
Hemoglobin [g / dL]
TAVR access [% transfemoral (n)]
Post-procedural stroke
Post-procedural death
Plasma ntProBNP [pg / mL]
Elevated NTproBNP
Plasma cTnT [pg / mL]
Elevated cTnT
LV mass index [g / m2]
LV mass [g]
LV remodeling type
Normal Geometry
Concentric remodeling
Concentric hypertrophy
Eccentric hypertrophy
LV ejection fraction [%]
LV stroke volume index [mL / m2]
LV end-diastolic diameter [mm]
LV end-systolic diameter [mm]

No/Mild LVH &
Normal cTnT
159
82.2 (75.7 – 87.2)
34.0% (54)
27.1 (23.9 – 31.6)
1.3% (2)
3.3 (2.2 – 4.7)
90.6% (144)
133 (121 – 147)
69 (60 – 76)
26.4% (42)
67.9% (108)
15.8% (25)
49.1% (78)
36.5% (58)
61.2 (47.3 – 77.5)
1.3% (2)

No/Mild LVH &
Elevated cTnT
305
84.0 (77.8 – 87.9)
40.0% (122)
27.8 (24.6 – 31.2)
3.9% (12)
4.4 (3.1 – 6.5)
94.8% (289)
130 (118 – 148)
68 (61 – 75)
43.0% (131)
74.4% (227)
26.2% (79)
26.2% (79)
45.4% (138)
47.9 (35.0 – 61.4)
3.6% (11)

No/Mild LVH &
Normal NTproBNP
145
82.0 (78.1 – 87.2)
34.5% (60)
28.0 (25.1 – 31.7)
4.1% (6)
3.3 (2.4 – 4.7)
91.0% (132)
130 (120 – 146)
67 (62 – 73)
35.2% (51)
75.9% (110)
18.6% (27)
53.1% (77)
22.8% (33)
55.5 (45.2 – 72.4)
0.0% (0)

No/Mild LVH &
Elevated NTproBNP
319
84.0 (76.6 – 87.9)
39.5% (126)
27.3 (23.8 – 30.8)
2.5% (84)
4.3 (3.0 – 6.4)
94.4% (301)
130 (118 – 148)
69 (60 – 76)
38.2% (122)
70.5% (225)
24.4% (77)
47.6% (152)
51.3% (163)
50.8 (36.1 – 68.0)
4.1% (13)

3.9% (6)
29.6% (45)
62.5% (95)
3.9% (6)
5.0% (8)
8.2% (13)
11.4% (18)
12.8 (11.8 –14.0)
91.8% (146)
1.4 (2)
0.6 (1)
767 (306 – 1338)
55.3 ( 88)
12.6 (9.0 – 16.6)
-95.1 (79.5 – 106.6)
176.0 (146.4 – 218.0)

3.8% (11)
24.3% (70)
58.0% (167)
13.9% (40)
12.1% (37)
4.6% (14)
10.9% (33)
12.0 (10.8 – 13.2)
87.2% (266)
2.3 (6)
2.0 (6)
1365 (630 – 3032)
75.7 (231)
33.2 (23.7 – 52.5)
-99.8 (84.7 – 110.3)
185.8 (156.7 – 221.7)

6.7% (9)
32.8% (44)
55.2% (74)
5.2% (7)
11.0% (16)
7.6% (11)
7.6% (11)
12.9 (11.7 – 14.0)
93.1% (135)
2.2 (3)
0.0 (0)
344 (206 – 504)
-19.1 (12.6 – 27.3)
51.0 ( 74)
94.2 (78.3 – 105.6)
170.8 (147.4 – 216.1)

2.6% (8)
23.2% (71)
61.4% (188)
12.7% (39)
9.1% (29)
5.0% (16)
12.6% (40)
12.1 (10.9 – 13.2)
86.8% (277)
1.8 (5)
2.2 (7)
1721 (1036 – 3354)
-26.1 (16.2 – 48.2)
72.4 (231)
99.8 (86.2 – 110.4)
186.9 (156.8 – 221.5)

5.7 (25)
67.3 (107)
12.6 (20)
4.4 (7)
62.6 (58.6 – 67.3)
37.1 (29.3 – 45.5)
42.6 (38.6 – 47.4)
27.9 (24.0 – 31.8)

12.1 (37)
56.4 (172)
27.2 (83)
4.3 (13)
61.6 (54.3 – 66.4)
34.8 (28.6 – 41.9)
43.0 (38.5 – 47.9)
28.2 (24.4 – 33.8)

12.4 (18)
71.7 (104)
14.5 (21)
1.4 (2)
64.1 (59.8 – 67.6)
40.3 (33.3 – 45.8)
42.3 (38.3 – 46.0)
26.7 (23.5 – 30.3)

13.8 (44)
54.9 (175)
25.7 (82)
5.6 (18)
61.1 (51.4 – 66.3)
33.4 (27.8 – 39.7)
43.4 (38.8 – 48.4)
28.8 (24.8 – 34.7)

p-value*

p-value†

0.0831
0.202
0.341
0.0992
<0.0011
0.0862
0.291
0.711
<0.0012
0.1382
0.0122
0.932
0.0652
0.211
0.152
0.0132

0.281
0.302
0.191
0.472
<0.0011
0.182
0.401
0.521
0.532
0.2352
0.172
0.282
<0.0012
0.0041
0.0142
0.0052

0.0142
0.122
0.862
<0.0011
0.142
0.262
-<0.0011
<0.001
<0.0011
-0.0151
0.0441
0.004

0.512
0.272
0.122
<0.0011
0.0472
0.072
-<0.0011
-<0.0011
<0.001
0.0011
0.0081
0.002

0.0301
0.0971
0.601
0.371

<0.0011
<0.0011
0.0331
<0.0011

LV relative wall thickness
[dimensionless]
LV septum thickness [mm]
LV posterior wall dimension [mm]
LV outflow tract diameter [mm]
AV area [mm2]
AV area index [mm2]
AV mean gradient [mmHg]
Aortic valve peak velocity [m / s]
Low flow
Moderate or severe AR
Moderate or severe MR

0.53 (0.45 – 0.62)
12.2 (10.6 – 13.5)
11.3 (10.1 – 12.4)
2.0 (1.9 – 2.1)
0.74 (0.62 – 0.85)
0.38 (0.31 – 0.45)
37.8 (32.3 – 45.2)
4.0 (3.7 – 4.4)
47.1% (74)
4.7% (7)
0.6% (1)

0.55 (0.45 – 0.65)
12.3 (11.2 – 13.7)
11.6 (10.5 – 12.9)
2.0 (1.9 – 2.1)
0.71 (0.58 – 0.86)
0.37 (0.31 – 0.45)
37.6 (29.9 – 48.5)
4.0 (3.6 – 4.5)
50.3% (150)
4.8% (14)
2.6% (8)

0.53 (0.45 – 0.64)
12.4 (11.2 – 13.4)
11.3 (10.1 – 12.4)
2.0 (1.9 – 2.1)
0.79 (0.69 – 0.90)
0.42 (0.35 – 0.47)
38.8 (32.3 – 44.9)
4.1 (3.7 – 4.4)
32.2% (46)
4.4% (6)
0.0% (0)

0.54 (0.45 – 0.64)

0.261

12.2 (11.0 – 13.8)
11.5 (10.4 – 12.9)
2.0 (1.9 – 2.1)
0.69 (0.55 – 0.82)
0.36 (0.29 – 0.43)
37.6 (29.5 – 49.2)
4.0 (3.6 – 4.5)
57.1% (178)
4.9% (15)
2.8% (9)

1

0.27
0.0251
0.751
0.311
0.321
0.781
0.811
0.5162
0.972
0.142

0.821
0.871
0.0691
0.0461
<0.0011
<0.0011
0.781
0.421
<0.0012
0.892
0.0432

Data for each characteristic is displayed as either a percentage (number of patients) or as median (IQR Q1 – IQR Q3 ). Statistical tests
used were 1Wilcoxon test or 2Pearson test. P-values represent T-tests between the specified groups: no/mild LVH *(normal cTnT vs
elevated cTnT) and †(normal NTproBNP vs elevated NTproBNP). N is the number of non-missing values. LV = left ventricular, AV =
aortic valve, AR = aortic regurgitation, MR = mitral regurgitation.
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Table S3. Baseline characteristics in the moderate/severe LVH group with respect to normal versus elevated biomarkers
Characteristic
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Patients [N]
Age [y]
Sex [% female (n)]
Body mass index [kg / m2]
Race [% non-white (n)]
STS score
Hypertension
SBP [mmHg]
DBP [mmHg]
Diabetes
Coronary artery disease
Myocardial infarction
Coronary Revascularization
Atrial fibrillation / flutter
Creatinine clearance [mL / min]
Dialysis
Heart failure class
NYHA I
NYHA II
NYHA III
NYHA IV
Oxygen-dependent lung disease
Active cancer
Prior stroke
Hemoglobin [g / dL]
TAVR access [% transfemoral (n)]
Post-procedural stroke
Post-procedural death
Plasma ntProBNP [pg / mL]
Elevated NTproBNP
Plasma cTnT [pg / mL]
Elevated cTnT
LV mass index [g / m2]
LV mass [g]
LV remodeling type
Normal Geometry
Concentric remodeling
Concentric hypertrophy
Eccentric hypertrophy
LV ejection fraction [%]
LV stroke volume index [mL / m2]
LV end-diastolic diameter [mm]
LV end-systolic diameter [mm]
LV relative wall thickness [dimensionless]

Mod/Sev LVH &
Normal cTnT
37
81.1 (74.3 – 85.9)
54.1% (20)
29.2 (25.7 – 33.1)
0% (0)
3.7 (2.7 – 4.9)
89.2% (33)
135 (125 – 154)
70 (64 – 78)
35.1% (13)
64.9% (24)
11.1% (4)
43.2% (16)
37.8% (14)
61.2 (45.0 – 71.7)
2.7% (1)

Mod/Sev LVH &
Elevated cTnT
173
84.4 (78.7 – 88.9)
57.2% (99)
26.0 (22.9 – 31.7)
94.2% (10)
5.4 (3.7 – 7.7)
92.5% (160)
132 (118 – 144)
68 (60 – 75)
36.0% (62)
70.5% (122)
24.7% (42)
43.9% (76)
40.5% (70)
43.7 (29.7 – 59.1)
4.6% (8)

Mod/Sev LVH &
Normal NTproBNP
29
84.2 (80.0 – 86.3)
34.5% (10)
31.7 (29.0 – 35.4)
3.4% (1)
4.1 (3.1 – 5.9)
100% (29)
133 (123 – 142)
67 (61 – 77)
31.0% (9)
79.3% (23)
13.8% (4)
58.6% (17)
24.1% (7)
58.8 (39.7 – 70.7)
3.4% (1)

Mod/Sev LVH & Elevated
NTproBNP
181
83.6 (76.9 – 88.8)
60.2% (109)
25.9 (22.8 – 30.8)
5.0% (9)
5.1 (3.6 – 7.5)
90.6% (164)
132.0 (118.0 – 146.0)
68 (61 – 76)
36.7% (66)
68.0% (123)
23.7% (42)
41.4% (75)
42.5% (77)
44.3 (31.4 –60.5)
4.4% (8)

2.8% (1)
25.0% (9)
61.1% (22)
11.1% (4)
2.7% (1)
8.1% (3)
16.2% (6)
11.8 (10.3 – 13.0)
89.2% (33)
0.000 (0)
0.000 (0)
715 (489 – 1514)
62.2 (23)
11.7 (9.6 – 15.4)
-136.1 (117.8 – 146.8)
261.5 (225.9 – 318.1)

3.0% (5)
24.2% (40)
56.4% (93)
16.4% (27)
8.7% (15)
3.5% (6)
13.3% (23)
12.1 (10.8 – 13.1)
84.4% (146)
0.007 (1)
0.012 (2)
3374 (1686 – 7902)
91.3 (158)
33.1 (26.0 – 47.4)
-141.2 (124.0 – 155.1)
257.4 (217.4 – 315.3)

3.6% (1)
42.9% (12)
46.4% (13)
7.1% (2)
6.9% (2)
13.8% (4)
17.2% (5)
12.0 (11.3 – 13.3)
89.7% (26)
0.000 (0)
0.000 (0)
474 (329 – 622)

2.9% (5)
21.4% (37)
59.0% (102)
16.8% (29)
7.7% (14)
2.8% (5)
13.3% (24)
12.1 (10.5 – 13.1)
84.5% (153)
0.006 (1)
0.011 (2)
3368 (1779 – 7706)

20.4 (14.4 – 31.0)
51.7 ( 15)
138.9 (124.7 – 147.3)
288.7 (254.9 – 331.7)

31.5 (22.1 – 45.5)
87.3 (158)
139.4 (122.4 – 154.7)
252.2 (212.2 – 311.5)

--81.1 (30)
18.9 (7)
64.3 (56.8 – 66.1)
40.3 (35.3 – 49.0)
47.0 (42.8 – 53.8)
28.4 (25.5 – 36.6)
0.57 (0.47 – 0.63)

--83.8 (145)
16.2 (28)
57.5 (44.4 – 63.3)
38.9 (29.9 – 45.8)
48.1 (43.2 – 53.9)
33.2 (29.0 – 40.8)
0.54 (0.46 – 0.65)

--86.2 (25)
13.8 (4)
62.5 (60.6 – 65.5)
41.6 (37.6 – 48.6)
49.2 (45.8 – 52.0)
31.3 (28.3 – 34.2)
0.57 (0.50 – 0.63)

--82.9 (150)
17.1 (31)
57.5 (44.4 – 63.7)
38.9 (30.1 – 45.9)
47.8 (42.7 – 54.1)
33.2 (27.7 – 41.3)
0.54 (0.46 – 0.65)

p-value*

p-value†

0.0151
0.722
0.0461
0.332
<0.0011
0.512
0.161
0.141
0.922
0.502
0.0752
0.942
0.772
<0.0011
0.602
0.882

0.841
0.0092
<0.0011
0.842
0.0341
0.0852
0.831
0.851
0.222
0.562
0.232
0.0832
0.062
0.0041
0.812
0.0822

0.212
0.212
0.642
0.591
0.462
0.511

0.872
0.0062
0.562
0.461
0.472
0.569

<0.0011
<0.001
<0.0011

<0.0011

0.191
0.631
0.685

<0.0011
<0.001
0.871
0.0231
0.655

<0.0011
0.111
0.911
0.0241
0.781

0.0011
0.0841
0.341
0.121
0.781

LV septum thickness [mm]
LV posterior wall dimension [mm]
LV outflow tract diameter [mm]
AV area [mm2]
AV area index [mm2]
AV mean gradient [mmHg]
Aortic valve peak velocity [m / s]
Low flow
Moderate or severe AR
Moderate or severe MR

14.0 (12.4 – 15.4)
13.0 (11.8 – 15.0)
2.07 (1.9 – 2.2)
0.74 (0.64 – 0.90)
0.40 (0.35 – 0.46)
39.8 (32.4 – 54.3)
4.1 (3.7 – 4.8)
24.3% (9)
0% (0)
5.4% (2)

13.8 (12.1 – 15.6)
13.0 (11.5 – 14.7)
2.0 (1.9 – 2.1)
0.71 (0.57 – 0.86)
0.39 (0.31 – 0.47)
40.9 (32.5 – 50.7)
4.1 (3.8 – 4.7)
36.8% (63)
3.6% (6)
8.1% (14)

14.4 (13.5 – 16.4)
13.2 (12.2 – 15.0)
2.1 (2.0 – 2.2)
0.85 (0.70 – 0.97)
0.42 (0.33 – 0.48)
42.5 (35.0 – 50.1)
4.1 (3.8 – 4.4)
17.2% (5)
3.4% (1)
3.4% (1)

13.6 (12.0 – 15.3)
13.0 (11.5 – 14.7)
2.00 (1.9 – 2.1)
0.71 (0.57 – 0.84)
0.39 (0.31 – 0.47)
40.6 (31.6 – 52.0)
4.1 (3.7 – 4.7)
37.4% (67)
2.9% (5)
8.3% (15)

0.531
0.831
0.201
0.111
0.421
0.901
0.801
0.1471
0.4502
0.572

0.0621
0.411
0.0071
0.0031
0.201
0.791
0.881
0.0341
0.282
0.362

Data for each characteristic is displayed as either a percentage (number of patients) or as median (IQR Q1 – IQR Q3 ). Statistical tests
used were 1Wilcoxon test or 2Pearson test. P-values represent T-tests between the specified groups: mod/sev LVH *(normal cTnT vs
elevated cTnT) and †(normal NTproBNP vs elevated NTproBNP). N is the number of non-missing values. LV = left ventricular, AV =
aortic valve, AR = aortic regurgitation, MR = mitral regurgitation.
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Table S4. Pairwise comparisons between the LVH groups
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cTnT
Females
NG
CR
CH
Males
NG
CR
CH
Females + Males
NG
CR
CH
NTproBNP
Females
NG
CR
CH
Males
NG
CR
CH
Females + Males
NG
CR
CH

CR

LV Remodeling Type
CH

EH

0.42
---

0.022
<0.001
--

0.26
0.34
0.41

0.73
---

0.021
0.002
--

0.19
0.13
0.63

0.61
---

0.051
<0.001
--

0.31
0.085
0.66

0.97
---

0.021
<0.001
--

0.009
<0.001
0.34

0.005
---

0.23
<0.001
--

0.049
<0.001
0.29

0.013
---

0.016
<0.001
--

0.003
<0.001
0.14

Pairwise comparisons between the LVH groups in the box-and-whisker plots shown in
Supplemental Figure 3. P-values from the Wilcoxon rank sum test are shown in each cell for
cTnT and NTproBNP in females, males, and both.

Table S5. Pairwise comparisons between the LVH groups

Downloaded from http://ahajournals.org by on December 7, 2022

cTnT
Females
No
Mild
Moderate
Males
No
Mild
Moderate
Females + Males
No
Mild
Moderate
NTproBNP
Females
No
Mild
Moderate
Males
No
Mild
Moderate
Females + Males
No
Mild
Moderate

Mild

LVH
Moderate

Severe

0.32
---

0.036
0.18
--

<0.001
0.001
0.094

0.012
---

0.31
0.31
--

0.001
0.45
0.10

0.052
---

0.13
0.93
--

<0.001
0.024
0.026

<0.001
---

<0.001
0.90
--

0.002
0.29
0.53

0.02
---

<0.001
0.11
--

<0.001
<0.001
0.002

<0.001
---

<0.001
0.29
--

<0.001
<0.001
0.006

Pairwise comparisons between the LVH groups in the box-and-whisker plots shown in
Supplemental Figure 3. P-values from the Wilcoxon rank sum test are shown in each cell for
cTnT and NTproBNP in females, males, and both.

Table S6. LVH, Biomarkers, and Kansas City Cardiomyopathy Questionnaire (KCCQ)
score
30-days
estimated KCCQ
(95% CI)
Model 1: LVH
Moderate/severe vs. no/mild LVH
Model 2: cTnT
Moderate/severe vs. no/mild LVH
Elevated vs. normal cTnT
Model 3: NTproBNP
Moderate/severe vs. no/mild LVH
Elevated vs. normal NTproBNP
Model 4: cTnT and NTproBNP
Moderate/severe vs. no/mild LVH
Elevated vs. normal cTnT
Elevated vs. normal NTproBNP

p-value

1-year
estimated KCCQ
(95% CI)

p-value

-1.04 (-5.11 – 3.12)

0.62

2.38 (-1.69 – 6.66)

0.29

-0.75 (-4.61 – 3.55)
-1.99 (-6.37 – 1.95)

0.72
0.38

2.65 (-1.33 – 6.78)
-2.58 (-6.77 – 2.01)

0.23
0.25

-0.62 (-4.56 – 3.70)
-2.55 (-7.02 – 1.37)

0.76
0.27

2.81 (-1.20 – 7.25)
-2.67 (-7.81 – 2.38)

0.2
0.26

-0.44 (-4.38 – 3.78)
-1.55 (-5.77 – 2.53)
-2.22 (-6.79 – 1.66)

0.83
0.49
0.38

2.96 (-0.90 – 7.32)
-2.24 (-7.37 – 2.89)
-2.17 (-6.15 – 2.50)

0.18
0.35
0.34

The estimated difference in KCCQ score at 30-days and 1-year post-TAVR are displayed for
four models. No KCCQ differences met statistical significance.
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Figure S1. CONSORT diagram

CONSORT diagram displaying patient inclusion and exclusion in the study.
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Figure S2. Box-and-whisker plots according to LVH severity
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Box-and-whisker plots according to LVH severity of the distribution of plasma cTnT and
NTproBNP versus LVH are shown for females, males, and females + males. The horizontal bar
in the box denotes the median. The upper and lower whiskers represent the 97.5 and 2.5
percentiles, respectively. Discrete plotted points represent data outside this range. Percentages
above bars indicate the frequency of biomarker elevation. P-values were generated from the
nonparametric Kruskal-Wallis test and pairwise comparisons from the Wilcoxon rank sum test
can be seen in Supplemental Table 4. On the rightmost side of the figure, stacked proportions
charts demonstrate the frequency of elevations in 0, 1, or 2 biomarkers with respect to LVH
severity in females, males, and both.

Figure S3. Box-and-whisker plots according to LV remodeling geometry
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Box-and-whisker plots according to LV remodeling geometry of the distribution of plasma cTnT
and NTproBNP versus LVH are shown for females, males, and females + males. The horizontal
bar in the box denotes the median. The upper and lower whiskers represent the 97.5 and 2.5
percentiles, respectively. Discrete plotted points represent data outside this range. Percentages
above bars indicate the frequency of biomarker elevation. P-values were generated from the
nonparametric Kruskal-Wallis test and pairwise comparisons from the Wilcoxon rank sum test
can be seen in Supplemental Table 3. On the rightmost side of the figure, stacked proportions
charts demonstrate the frequency of elevations in 0, 1, or 2 biomarkers with respect to LV
geometry in females, males, and both. ‘NG’ = normal geometry, ‘CR’ = concentric remodeling,
‘CH’ = concentric hypertrophy, and ‘EH’ = eccentric hypertrophy.

